Investigators reported a pediatric liver recipient who developed symptomatic infection after transplantation; the clinical and laboratory record points toward a donor-derived origin. The deceased donor resided in a region where Ehrlichia ewingii has been identified in Amblyomma americanum ticks and where human cases occurred. The donor had a transient, self-limited illness about 30 days before organ procurement. Retrospective serology on donor serum detected IgG reactive with E. chaffeensis at a titer of 1:2,048, a finding the study team noted as evidence of prior Ehrlichia exposure.
PCR testing of donor serum and of the recipient's whole-blood sample collected on the day of transplantation did not detect Ehrlichia DNA, and liver allograft biopsy specimens tested negative by immunohistochemistry and PCR. Those negative results were documented by the authors and temper the strength of direct microbiologic proof in donor tissue. Still, the geographical exposure, compatible donor illness, and subsequent recipient PCR confirmation supported the investigators’ classification of this case as likely donor-derived.
The patient was a child aged between 10 and 15 years who underwent deceased-donor liver transplantation for end-stage liver disease due to primary sclerosing cholangitis. The procedure itself was uncomplicated. Eighteen days posttransplant, clinicians recorded fever, headache, dyspnea, and severe nausea, accompanied by anemia, leukopenia, and thrombocytopenia. Respiratory deterioration developed over 72 hours with progressive tachypnea and falling oxygen saturation; fever peaked at 40.5°C.
Empiric broad testing including blood and urine cultures was negative, and imaging revealed no acute abnormalities. The study authors noted the patient had no travel outside the transplant state in the preceding 10 weeks and lacked known outdoor or animal exposures or tick bites.
Peripheral blood smear at the time of doxycycline initiation demonstrated morulae within granulocytes, a hematologic clue suggestive of Ehrlichia or Anaplasma infection. Mayo Clinic performed real-time PCR on whole-blood samples collected 24 days after transplantation; results were positive for Ehrlichia ewingii and also positive on subsequent samples. CDC confirmatory real-time PCR detected Ehrlichia spp. DNA but not E. chaffeensis DNA; partial 16S rRNA sequencing later confirmed E. ewingii DNA.
Serial whole-blood PCRs from the liver recipient collected on days 35, 42, 49, and 56 after transplantation remained positive. PCR testing converted to negative on days 67 and 68, at which point clinicians discontinued doxycycline briefly. On day 98, PCR again returned positive. The authors reported alternating negative and positive PCR results thereafter, consistent with persistent low-level bacteremia while the patient remained clinically asymptomatic. Serologic testing for antibodies reactive to E. chaffeensis remained negative in the recipient throughout follow-up.
Clinicians initiated intravenous doxycycline (100 mg twice daily) on day 24 after transplantation for suspected atypical pneumonia and tickborne disease. The patient’s fever resolved within 24 hours of starting therapy, and clinical and laboratory abnormalities improved rapidly, according to the clinical team. Given concerns about trimethoprim/sulfamethoxazole in the setting of rickettsial infections, providers switched Pneumocystis jirovecii prophylaxis from oral trimethoprim/sulfamethoxazole to inhaled pentamidine.
Because of persistently positive PCR results and intermittent reemergence of detectable DNA, clinicians continued doxycycline for an extended period exceeding 273 days. The report documents the prolonged antimicrobial course but does not provide a formal protocol or prespecified duration; the authors stated the extended treatment decision reflected clinical judgment in the context of immunosuppression and intermittent PCR positivity.
State health departments collaborated with CDC to investigate. CDC performed retrospective serology and PCR testing on donor samples; serology was positive at a high titer, while PCR of donor serum was negative. Liver allograft biopsies were negative by immunohistochemistry and PCR. The donor's clinical episode preceding death aligned temporally with possible recent tickborne infection, the investigators reported.
Both donor kidneys were transplanted into other recipients. The treating clinicians for those kidney recipients were notified; neither reported signs or symptoms consistent with ehrlichiosis. Whole-blood PCRs from both kidney recipients were negative for Ehrlichia spp., and serologic testing was not performed.
The authors acknowledged several limitations inherent to the investigation. CDC did not detect Ehrlichia DNA in donor serum or in pretransplant recipient blood, and liver biopsy specimens were negative for antigen and DNA—findings that limit direct molecular proof of donor-derived infection. Serologic testing was not performed for the kidney recipients, leaving uncertainty about subclinical transmission to those organs. The recipient remained intermittently PCR-positive despite prolonged doxycycline, and serology remained negative, raising questions about the kinetics of antibody response in immunosuppressed hosts that the study could not resolve.
Follow-up was incomplete: the report documents that the patient did not return for the requested infectious disease visit at a later time point. The authors therefore could not provide final long-term outcomes beyond the >273-day treatment period. These gaps define specific unanswered clinical questions about optimal treatment duration, the value of serial PCR versus serology in immunocompromised patients, and the frequency of donor-derived transmission for rare tickborne pathogens.